The adaptive growth of the uterus during gestation involves gradual changes in cellular phenotypes from the early proliferative to the intermediate synthetic phase of cellular hypertrophy, ending in the final contractile/labour phenotype. The mammalian target of rapamycin (mTOR) signaling pathway regulates cell growth and proliferation in many tissues. We hypothesized that mTOR was a mediator of hormone-initiated myometrial hyperplasia during gestation. The protein expression and phosphorylation levels of mTOR, its upstream regulators [insulin receptor substrate-1, phosphoinositide-3-kinase (PI3K), Akt], and downstream effectors [S6-kinase-1 (S6K1) and eI4FE-binding protein 1 (4EBP1)] were analyzed throughout normal pregnancy in rats. In addition, we used an ovariectomized (OVX) rat model to analyze the modulation of the mTOR pathway and proliferative activity of the uterine myocytes by estradiol alone and in combination with the mTOR-specific inhibitor rapamycin. Our results demonstrate that insulin receptor substrate-1 protein levels and the phosphorylated (activated) forms of PI3K, mTOR, and S6K1 were significantly up-regulated in the rat myometrium during the proliferative phase of pregnancy. Treatment of the OVX rats with estradiol caused a transient increase in IGF-I followed by an up-regulation of the PI3K/mTOR pathway, which became apparent by a cascade of phosphorylation reactions (P-P85, P-Akt, P-mTOR, P-S6K1, and P-4EBP1). Rapamycin blocked activation of P-mTOR, P-S6K1, and P-4EBP1 proteins and significantly reduced the number of proliferating cells in the myometrium of OVX rats. Our in vivo data demonstrate that estradiol was able to activate the PI3K/mTOR signaling pathway in uterine myocytes and suggest that this activation is responsible for the induction of myometrial hyperplasia during early gestation. (Endocrinology 150: 4672-4680, 2009) 
T he growth and differentiation of cell types within the uterus is critically important for the successful completion of pregnancy (1) . During normal human pregnancy, the uterus grows from a weight of about 50 g in the nonpregnant state to about 1200 g at term, representing a remarkable 24-fold increase in mass (2) . The myometrium, or muscular layer of the uterus, is primarily composed of bundles of smooth muscle cells (SMCs) embedded in an extracellular matrix and contributes to a major proportion of uterine growth during pregnancy (3) . The increase in myometrial growth occurs by two separate mechanisms: an increase in cell number (hyperplasia) and an increase in cell size (hypertrophy) (4, 5) . The size and number of myometrial SMCs are determined by the stage of pregnancy (6) . We reported earlier that the adaptive growth of the myometrium during gestation involves gradual changes in cellular phenotypes from the early proliferative to the intermediate synthetic, ending in the final contractile/labor phenotype (7) . During labor, the primary function of the myometrium is to generate highamplitude, forceful contractions sufficient to expel the fetus to the extrauterine environment.
Female sex hormones regulate several different cellular functions in the uterus, including growth and differentiation (8, 9) . We reported that during the early phase of rat pregnancy, uterine myocytes undergo hyperplasia, confirmed by increased 5-bromo-2Ј-deoxyuridine incorporation, as well as proliferating nuclear cell antigen expression (10) . A significant literature documents the action of estrogens on myometrial hyperplasia in nonpregnant animals (11, 12) . Multiple studies reported that estrogens regulate mitosis in the uterine epithelia and stroma during physiological (pregnancy) and pathological (leiomyoma) growth. 17␤-Estradiol (E 2 ), in particular, has been shown to be important in exerting these effects. Compared with controls, E 2 significantly induced G 1 cell cycle progression and proliferation in uterine smooth muscle-and leiomyoma-derived cells (13) . E 2 -stimulated uterine growth in ovariectomized (OVX) rats is accompanied by cell division, the inhibition of which by mitotic inhibitors subsequently inhibits myometrial hypertrophy, highlighting the importance of cell division to uterine and more specifically, myometrial growth (14) .
For many organs, growth factor signaling plays a central role in mediating the effects of steroid hormones (15) . The IGF (insulin-like growth factor) system regulates cell proliferation and differentiation in a variety of tissues (16) . IGF-I and epidermal growth factor mediate uterine hyperplasia in nonpregnant rodents (12, 17) . In the uterus, IGF-I signaling is an important regulator of the effects of E 2 (11, 15) . Uterine IGF-I signaling can be initiated by estradiol acting through its nuclear receptor (estrogen receptor) to stimulate the local synthesis of IGF-I (18). Sahlin and colleagues showed that estradiol administration to OVX animals increased uterine estrogen receptor and IGF-I mRNA expression (19) . We showed that IGF-I gene expression was up-regulated during the estrogencontrolled proliferative phase of rat pregnancy (7) . Recent literature has confirmed that E 2 and IGF-I signaling pathways are intertwined because blocking IGF signaling in human endometrial carcinoma cells reduces the proliferative effect of E 2 (20) . Thus, both estrogens and IGF-I play a major role in cellular proliferation and growth forming a basis for the hypothesis that these two molecules mediate the hyperplasia of uterine myocytes during the proliferative phase of pregnancy. E 2 and IGF-I activate phosphoinositide-3-kinase (PI3K) signaling, which leads to cellular proliferation and growth in reproductive tissues (21) . The binding of insulin or IGFs to their receptors, leads to the recruitment and phosphorylation of the insulin receptor substrate (IRS), and subsequent recruitment of PI3K (22) . PI3K activation by growth factors is followed by a cascade of phosphorylation reactions leading to the activation of the mammalian target of rapamycin (mTOR). Akt (also known as protein kinase B) is a serine/threonine kinase that is phosphorylated in response to PI3K activation and positively regulates mTOR activity. mTOR is a serine/threonine kinase that is essential for cellular growth and development and is involved in regulating cell cycle progression, cell size, and survival in many tissues (23) (24) (25) , processes that can be blocked by the mTOR-specific inhibitor, rapamycin (RAPA) (22) . The mTOR protein forms two distinct multiprotein complexes, mTORC1 and mTORC2 (26) . Activation of the mTORC1 pathway is RAPA sensitive and leads to the activation of protein synthesis, metabolism, ribosome biogenesis, and transcription (22) . The mTORC2 complex is RAPA insensitive, and its activation regulates the actin cytoskeleton and cell polarity.
The most well-characterized downstream targets of mTOR are S6-kinase-1 (S6K1) and eI4FE-binding protein 1 (4EBP1). S6K1 phosphorylates the S6 protein of the 40S ribosomal subunit (26) , which leads to increased ribosomal biogenesis and thus an increased cellular capacity for protein synthesis (23) . 4EBP1 is a translational repressor that blocks the assembly of initiation factor complexes required for protein translation (27) . 4EBP1 is inactivated by mTOR phosphorylation (26) .
We hypothesize that the mTOR signaling pathway plays a major role in the growth of uterine myocytes during pregnancy and contributes to the induction and maintenance of the myometrial proliferative phenotype. Our study used a well-characterized in vivo rat model to test this hypothesis. In this study we: 1) investigated the protein expression levels and activation status of mTOR as well as its upstream regulators (IRS-1, PI3K, Akt) and downstream effectors (S6K1, 4EBP1) in the rat myometrium throughout gestation; 2) analyzed the role of E 2 in activating IGF-I expression and the mTOR pathway initiation and 3) analyzed the role of E 2 in inducing myometrial hyperplasia using an in vivo OVX rat model; and 4) determined the effect of RAPA on the E 2 -induced activation of the mTOR signaling pathway and on the proliferative activity of the uterine myocytes inE 2 -stimulated OVX rats.
Materials and Methods

Animals
Wistar rats (Charles River Co., St. Constance, Canada) were housed individually under standard environmental conditions 
Experimental protocol
Normal pregnancy and term labor
Animals were euthanized by carbon dioxide (CO 2 ), inhalation and myometrial tissue samples were collected on gestational d 0 and 6, 12, 14, 15, 19, 21, 22 , and 4 d postpartum (4PP). For each day of gestation, tissue was collected from four different animals and processed separately (n ϭ 4).
OVX rats
Ovariectomy was performed on virgin Wistar rats under general anesthesia via isoflurane inhalation. Bilateral flank incisions were made from both sides of the animal, and the ovaries were removed using fine scissors. Rats were allowed to recover for 7 d to ensure that the endogenous levels of estrogens were reduced (19) and were then injected with E 2 or E 2 plus RAPA at different time points. Animals were euthanized by CO 2 inhalation and myometrial samples were collected for biochemical and immunohistochemical analysis.
Injections
The OVX animals were split into three groups. Group 1 consisted of 16 animals treated with sc injections of E 2 only (4 g/ kg ⅐ d per rat at each treatment time point) or vehicle (10% ethanol and 90% corn oil) (19) . Group 2 consisted of 16 animals treated with sc injections of E 2 plus ip injections of RAPA (two injections of RAPA in a 24 h interval prior to E 2 injections, 2 mg/kg ⅐ d per rat) or vehicle (5% dimethylsulfoxide and 0.2% carboxymethylcellulose) (28) . Within these groups, animals (n ϭ 4) were euthanized at 0, 3, 6, or 24 h (Fig. 1) . Group 3 consisted of animals treated twice with RAPA only and the uterine tissues were collected at the same time intervals only for immunohistochemical analysis.
Tissue collection
For protein extraction, the uterine horns were placed into ice-cold PBS, bisected longitudinally, and dissected away from both pups and placentas. The endometrium was carefully removed from the myometrial tissue by mechanical scraping on ice, eliminating the entire luminal epithelium and the majority of the uterine stroma. The myometrial tissue was flash frozen in liquid nitrogen and stored at Ϫ80 C. For immunohistochemical studies, the uterine horns were cross-sectioned or sectioned longitudinally and placed in formalin for fixation.
Western immunoblot analysis
Frozen myometrial tissue was crushed under liquid nitrogen using a mortar and pestle, homogenized (Ultra-Turrax T-25; IKA-Labortechnick, Staufen, Germany) for 1 min in radioimmunoprecipitation assay lysis buffer [50 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1% (vol/vol) Triton X-100, 1% (vol/vol) sodium deoxycholate, 0.1% (wt/vol) sodium dodecyl sulfate], and supplemented with 100 M sodium orthovanadate and a protease inhibitor cocktail tablet (Complete Mini; Roche, Québec, Canada). Samples were spun at 12,000 ϫ g for 15 min at 4 C, and the supernatant was transferred to a fresh tube to obtain a crude protein lysate. Protein concentrations were determined using a protein assay buffer (Bio-Rad, Hercules, CA). Proteins were resolved by electrophoresis on precast 3-8% Tris-acetate polyacrylamide gels (Invitrogen, Carlsbad, CA) for measuring mTOR and IRS-1 expression, on 12% precast Tris-glycine polyacrylamide gels (Invitrogen) for measuring IGF-I expression, and on 10% sodium dodecyl sulfate-polyacrylamide gels for measuring PI3K, Akt, S6K1, and 4EBP1 expression. Proteins were transferred onto polyvinylidene difluoride membranes (Millipore, Bedford, MA). Total protein expression levels of IGF-I, IRS-1, P85, Akt, mTOR, S6K1, and 4EBP1 proteins as well as the activated (phosphorylated) forms of these proteins were measured by immunoblot analysis using primary and secondary antibodies (see supplemental Table 1 , published as supplemental data on The Endocrine Society's Journals Online web site at http://endo.endojournals.org). Probed membranes were developed using the Bio-Rad chemiluminescent detection system and analyzed using densitometry (Quantity One; Bio-Rad).
Immunohistochemistry
The formalin-fixed myometrial tissues were gradually dehydrated in ethanol and embedded in paraffin. Sections of 5 m thickness were collected on Superfrost Plus slides (Fisher Scientific Ltd., Nepean, Ontario, Canada). Paraffin sections were deparaffinized and rehydrated. After immersion in 3% hydrogen peroxide (Fisher Scientific), the antigens were unmasked using a microwave heating retrieval treatment in 10 mM sodium citrate solution (pH 6), blocked with protein serum-free blocking solution (Dako Corp., Carpinteria, CA), and incubated with primary Ki67 monoclonal rabbit antibody (see supplemental Table  1 ). For the negative controls, ChromPure nonspecific mouse IgGs were used at the same concentration, and sections were also FIG. 1. Scheme of injections and tissue collection. OVX rats were treated with E 2 (group 1), E 2 ϩRAPA (group 2), or RAPA only (group 3). Uterine tissues were collected at 3-, 6-, and 24-h time points. Tissue from control animals was collected at time 0. The E 2 injections were given sc, and the RAPA injections were given ip. The maximal dose of E 2 was 12 g/kg ⅐ d. This was divided into three doses of 4 g/kg. At time 0, all treated animals [group 1, E 2 only (n ϭ 12) and group 2, E 2 ϩRAPA (n ϭ 12)] were injected with the first dose of E 2 . Group 2 (E 2 ϩRAPA) also received a second injection of RAPA at this time point. In 3 h time (t ϭ 3 h), the first four animals from groups 1 and 2 were euthanized, and myometrial tissues were collected for analysis. At this 3 h time point, the rest of group 1 (eight animals) and group 2 (eight animals) were given the second injection of E 2 . After 3 h (t ϭ 6 h), four animals from group 1 and four animals from group 2 were killed and myometrial tissues were collected for analysis. At this 6 h time point, the rest of the group1 (four rats) and group 2 (four rats) were given the final (third) injection of E 2 . These remaining animals were euthanized exactly 24 h after the first injection of E 2 and tissues were collected for analyses. All myometrial tissues were processed separately. White arrows represent the day of OVX surgery, black arrows represent the time of estradiol injection, gray arrows represent the time of rapamycin injection, and black arrowheads represent the time of tissue collection.
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Real-time PCR analysis
Reverse transcription
Total RNA was extracted from the frozen tissues using TRIZOL (Life Technologies, Inc., Burlington, Ontario, Canada) according to the manufacturer's instructions. RNA samples were column purified using RNeasy minikit (QIAGEN, Mississauga, Ontario, Canada) and treated with 2.5 l deoxyribonuclease I (2.73 Kunitz U/l; QIAGEN) to remove genomic DNA contamination. Two micrograms of total RNA were primed with random hexamers to synthesize single-strand cDNAs in a total reaction volume of 100 l using the TaqMan reverse transcription kit (Applied Biosystems, Foster City, CA). To check whether the deoxyribonuclease treatment successfully eliminated all genomic DNA in the RNA samples, a RT(Ϫ) control was prepared the same way as the other total RNA samples except no reverse transcriptase was added. The thermal cycling parameters of reverse transcription were as follows: hexamer incubation at 25 C for 10 min, 42 C for 30 min, followed by reverse transcriptase inactivation at 95 C for 5 min.
Real-time PCR protocol
Twenty nanograms of cDNA from the previous step were subjected to real-time PCR using a specific set of primers (see Ref.
7) in a total reaction volume of 25 l (Applied Biosystems). Real-time PCR was performed in an optical 96-well plate with an ABI PRISM 7900 HT sequence detection system (Applied Biosystems), using the SYBR Green detection chemistry as described earlier (see Ref. 7) . A cycle threshold (CT) value was recorded for each sample. PCRs were set up in triplicate. Relative quantitation of gene expression was used to compare the difference in mRNA levels in response to E 2 treatment. An arithmetic formula from the comparative CT method (or ⌬⌬CT method; see ABI user bulletin 2) was applied to the raw CT values to extract relative gene expression data. Validation experiments were performed to ensure the PCR amplification efficiencies between the target gene and the housekeeping gene were similar. Ribosomal 18S was the housekeeping gene used for normalization (see Ref. 7) . mRNA levels for different treatment times (3, 6, and 24 h) were expressed as fold changes relative to the nontreated controls (time 0).
Statistical analysis
Gestational profiles were subjected to a one-way ANOVA followed by pairwise multiple comparison procedures (StudentNewman-Kuels post hoc test) to determine differences between groups. Immunoblots of OVX samples were subjected to gel documentation analysis at the same time. All E 2 treatment groups were subjected to a two-way ANOVA followed by pairwise multiple comparison procedures (Tukey post hoc test). Statistical analysis was carried out using Sigma Stat version 3.1 (San Jose, CA) with the level of significance for comparison set at P Ͻ 0.05.
Results
Expression and activation of mTOR and its upstream regulators and downstream effectors throughout gestation
Myometrial expression of IRS-1 as well as phosphorylated (activated) P85 (regulatory subunit of PI3K), Akt, mTOR, S6K1, and 4EBP1 proteins was analyzed throughout gestation. Phospho-IRS-1 was expressed equally throughout gestation (data not shown). The expression of total IRS, on the other hand, remained high throughout the proliferative phase of gestation and was then significantly down-regulated throughout the remainder of pregnancy [d 6 (P Ͻ 0.001), 12 (P Ͻ 0.05), and 14 (P Ͻ 0.05) compared with d 22 (Fig. 2, A and B) ]. PI3K is composed of an 85-kDa regulatory subunit and a 110-kDa catalytic subunit (29) . P85 protein was expressed equally throughout gestation; however, the activated form of P85, phospho-P85, was significantly increased during the proliferative phase of pregnancy on d 6 (P Ͻ 0.001), 12 (P Ͻ 0.001), and 14 (P Ͻ 0.05), compared with the nonpregnant samples (Fig. 2, A and C) . The levels of nonphosphorylated and phosphorylated forms of Akt remained fairly constant throughout gestation (data not shown). Total mTOR was expressed equally throughout gestation (data not shown). Similar to IRS-1 and phospho-P85 proteins, phospho-mTOR expression was high during early pregnancy but was significantly down-regulated at the end of pregnancy [d 6 (P Ͻ 0.05), 12 (P Ͻ 0.05), 14 (P Ͻ 0.001), and 15 (P Ͻ 0.05) of gestation compared with d 22 (Fig. 2, A and D) ].
To further determine whether the increase in mTOR activity was associated with an increase in its downstream effectors, we measured the expression levels of S6K1 and 4EBP1 throughout gestation as well as the activation status of both proteins. S6K1 was expressed equally throughout gestation. For the activated phospho-S6K1 protein, we found a similar activation pattern to mTOR and P85; there was an up-regulation of phospho-S6K1 expression on d 6 (P Ͻ 0.05), 12 (P Ͻ 0.05), 14 (P Ͻ 0.05), and 15 (P Ͻ 0.05) of gestation compared with nonpregnant samples (Fig. 2, A and E) . Both the total and phosphorylated forms of 4EBP1 were expressed equally throughout gestation (data not shown).
We hypothesize that the mTOR pathway regulates myometrial proliferation; thus, its specific inhibitor RAPA will affect the proliferative activity of uterine SMCs during gestation. We injected pregnant rats with RAPA at different gestational days to examine the effect of this drug on uterine myocyte proliferation. There was a significant reduction in uterine size in the animals treated with RAPA compared with vehicle-treated controls. The uterine horns were not only smaller but also less vascularized than those of the controls (data not shown). We found, however, that all fetuses had resorbed as a result of mTOR inhibition, confirming mTOR's pivotal role in fetal growth and development during gestation. Because using in vivo model of pregnancy was not informative, we turned to a nonpregnant animal model. To determine whether mTOR mediates hormone-regulated myocyte proliferation, we examine the potential role of estrogens in activating the mTOR pathway in myometrium of OVX rats.
Estradiol activates IGF-I gene and protein expression in the myometrium of OVX rats
First, we used an OVX rat model to examine whether exogenous E 2 administration can activate myometrial IGF-I gene and protein expression. Relative abundance of IGF-I gene transcripts in the myometrium was studied using real-time PCR. IGF-I mRNA was detected in the myometrium of OVX control animals, whereas the treatment of OVX rats with E 2 caused a transient increase in IGF-I mRNA levels. The transcript levels of IGF-I increased by 3 h of treatment (P Ͻ 0.05), rose further at 6 h (P Ͻ 0.05), and returned to the nontreated level by 24 h (Fig. 3A) . IGF-I protein levels were detected as double bands representing both IGF-I isoforms (IGF-IA and IGF-IB). IGF-I protein expression was significantly up-regulated after 6 h of estrogen treatment (P Ͻ 0.05), relative to nontreated controls (Fig. 3B ).
E 2 activates the mTOR pathway in the myometrium of OVX rats
Second, to study the effects of E 2 on the activation of the mTOR pathway in the OVX rat myometrium, we performed immunoblot analysis. We found that total IRS-1 protein levels were significantly up-regulated in response to 6 h of E 2 treatment, relative to nontreated controls (P Ͻ 0.05, Fig. 4, A and B) . We also found a statistically significant up-regulation of phospho-P85 after 3 (P Ͻ 0.001) and 6 h (P Ͻ 0.001) of E 2 treatment in the myometrium of OVX animals, relative to nontreated controls (Fig. 4, A   FIG. 3 . Effect of E 2 on IGF-I gene and protein expression in the myometrium of OVX rats. A, IGF-I mRNA levels were analyzed by realtime PCR using specific forward and reverse primers (see Ref. 7) , normalized to 18S mRNAs. B, Immunoblot and densitometric analysis illustrating the protein levels of IGF-I isoforms (IGF-IA, white bars, and IGF-IB, black bars) normalized to ␣-tubulin. E 2 -stimulated IGF-I mRNA and protein levels were expressed in fold changes relative to control (t ϭ 0) samples. The bars represent mean Ϯ SD (n ϭ 3-4 at each time point). *, A significant difference from control (t ϭ 0) samples (P Ͻ 0.05).
and C). Phospho (P)-Akt expression was up-regulated in the animals treated with E 2 for 3 h (P Ͻ 0.001) (Fig. 4 , A and D), whereas P-mTOR expression was up-regulated in the animals treated with E 2 for both 3 (P Ͻ 0.05) and 6 h (P Ͻ 0.05) (Fig. 4, A and E) . P-S6K expression was significantly up-regulated in the animals treated with E 2 for 6 h (P Ͻ 0.05) (Fig. 4, A and F) , whereas P-4EBP1 expression was up-regulated at 3 (P Ͻ 0.001), 6 (P Ͻ 0.001), and 24 h (P Ͻ 0.05) of E 2 treatment (Fig. 4, A  and G) . The expression of the total levels of the above mentioned proteins was equal across treatment times (data not shown).
We did not detect a difference in expression of IRS-1 and P-P85 between the E 2 and E 2 ϩRAPA treatment groups because these proteins are upstream of mTOR and as a result has not sensed the inhibitory effect of RAPA. P-Akt expression, on the other hand, was significantly down-regulated in the control animals of the E 2 ϩRAPA group (P Ͻ 0.05) relative to the control animals in the E 2 group (Fig. 4D) . RAPA treatment prevented the E 2 -induced increase in P-mTOR, P-S6K1, and P-4EBP1 protein expression. P-mTOR expression in the myometrium of OVX rats treated with RAPA was significantly reduced at 3 (P Ͻ 0.05) and 6 h (P Ͻ 0.001) compared with E 2 -onlytreated animals (Fig. 4E) . Similarly, P-S6K1 expression in the RAPA-treated animals was significantly reduced compared with that of the E 2 -treated animals at both 3 (P Ͻ 0.05) and 6 h (P Ͻ 0.05) (Fig. 4F) . P-4EBP1 also followed this expression pattern at 3 (P Ͻ 0.001) and 6 h (P Ͻ 0.001) compared with nontreated animals (Fig. 4G) .
The mTOR signaling pathway mediates E 2 -initiated myometrial hyperplasia in the OVX rat model
Immunohistochemical analysis was performed on the OVX uterine tissue to identify the level of proliferative activity of the myometrial cells after E 2 treatment and the effect of RAPA on this process. A common marker of proliferating cells, Ki67, was used in our analysis (30) . There were very few Ki67-positive cells in the sections from OVX control (nontreated) animals. We found a statistically significant increase in the number of Ki67-positive cells in both the circular and longitudinal smooth muscle layers in the myometrium of OVX animals treated with E 2 for 6 (P Ͻ 0.05) and 24 h (P Ͻ 0.001) compared with nontreated controls (Fig. 5, A and B) . The myometrium of OVX animals treated with E 2 ϩRAPA for 3 (P Ͻ 0.05), 6 (P Ͻ 0.001), and 24 h (P Ͻ 0.001) showed a statistically significant reduction in the number of Ki67-positive cells relative to E 2 -only controls (Fig. 5, A and B) . We looked at an additional group of rats that were treated solely with RAPA and found that there was no change in the proliferative status of the cells at all time points relative to nontreated controls (data not shown).
Discussion
We set out to determine whether the mTOR signaling pathway played a role in myometrial growth and differentiation during pregnancy. First, our data demonstrate that IRS-1, PI3K (P85), Akt, mTOR, S6K1, and 4EBP1 proteins are expressed in the rat myometrium throughout gestation. Moreover, total IRS-1 and the phosphorylated (active) forms of P85, mTOR, and S6K1 were significantly up-regulated during the hormone-regulated proliferative Capital letters represent differences among E 2 -treated samples and lowercase letters represent differences among E 2 ϩRAPA-treated samples. A significant difference between E 2 -and E 2 ϩRAPA-treated animals within the same treatment time point is indicated (*, P Ͻ 0.05; **, P Ͻ 0.001).
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phase of myometrial differentiation, suggesting activation of the PI3K/mTOR pathway. We reported earlier that the IGF pathway was also up-regulated during this phase of gestation (7). IGF-I has been implicated as autocrine/paracrine mediator of estrogen action in the rodent uterus (12).
Although we do not have direct evidence that estrogens can activate mTOR pathway during gestation, we have evidence that IGF-I is required for this activation. We detected that there was an increase in the IGF-I growth factor expression in rat myometrium after E 2 injections. Therefore, to determine whether there was a link between E 2 levels, IGF-I activation, and mTOR signaling, we studied the mTOR pathway status in myometrial tissue collected from OVX rats treated with E 2 . We discovered that all components of the PI3K/mTOR signaling pathway (IRS-1, P85, Akt, mTOR, S6K1, and 4EBP1) were transiently activated in response to E 2 , followed by an increase in the proliferative activity of myometrial SMCs. Earlier studies demonstrated that the specific inhibitor of mTOR, RAPA, inhibited proliferation of vascular SMCs (31) and smooth muscle-derived uterine cells (13) . In the current study, RAPA blocked both the E 2 -induced activation of the mTOR signaling pathway in the myometrium of OVX rats and the proliferative activity of the uterine SMCs. Our data are in accordance with previous in vitro findings demonstrating that the PI3K/mTOR signaling pathway is required for estrogen-induced proliferation in uterine leiomyoma-and myometrium-derived cell lines (13) . IRS-1 is a major signaling molecule activated by the insulin and IGF-I receptors. Treatment of CHO and breast cancer cell lines with E 2 up-regulates IRS1 gene and protein expression (32) . Our data suggest a similar effect of E 2 on myometrial IRS1 protein expression during rat pregnancy as well as in response to E 2 treatment in the OVX rats. mTOR is an evolutionarily conserved kinase that regulates both cell growth and cell cycle progression through its ability to integrate signals from nutrients and growth factors (33) . mTOR, a 268-kDa protein, is a member of the PI3K-kinase-related kinase superfamily (34) . All mammalian PI3K-kinase-related kinase family members appear to function in cell cycle checkpoint control (34) . PI3K, similar to mTOR, is important for a wide variety of cellular processes including cell growth, cell cycle progression and proliferation, and cell survival (25) . Both mTORand PI3K-dependent signals coordinately control the translational effectors S6K1 and 4EBP1. We found that the activated forms of PI3K (P85), mTOR, and its downstream target S6K1 were up-regulated during the proliferative phase of rat gestation, suggesting that PI3K mediates the activation of mTOR signaling. PI3K is activated in response to growth factors and hormones such as IGF-I and insulin (29) . Thus, the phosphorylation of P85 during the proliferative phase of pregnancy was likely in response to E 2 -induced IGF-I expression. Our in vivo data using OVX rats further confirms the ability of E 2 to induce the PI3K pathway because P85 was significantly activated in response to E 2 treatment. Capital letters represent differences among E 2 -treated samples, and lower-case letters represent differences among E 2 ϩRAPA-treated samples. A significant difference between E 2 and E 2 ϩRAPA-treated animals within the same treatment time point is indicated (*, P Ͻ 0.05; **, P Ͻ 0.001).
Akt activates the mTOR pathway by phosphorylating and inactivating tuberous sclerosis complex (TSC)-2, which acts as an upstream negative regulator of mTOR. This critical function of Akt led us to hypothesize that it may represent a component of the mTOR activation pathway in the myometrium. Whereas P-Akt was up-regulated in the OVX rat myometrium in response to E 2 treatment, this protein was expressed equally throughout gestation. It may be that during pregnancy, other kinases, i.e. one of MAPKs (Erk1/2), can act in parallel with Akt, to phosphorylate TSC2 and relieve its inhibition of mTOR. Roux et al. (35) showed that the MAPK pathway targets TSC2, as evidenced by the observation that expression of an activated allele of ras induces phosphorylation of TSC2. Another study demonstrated that activated Erk 1/2 directly phosphorylates TSC2 at sites that differ from the Akt target sites (36) . Our preliminary data show an increase in Erk1/2 activation during the proliferative phase of gestation, relative to nonpregnant controls (data not shown). Thus, the PI3K/Akt and Ras/Erk signaling pathways converge on TSC1-TSC2, resulting in TSC2 inactivation and ultimately mTORC1 activation (22) . Consistent with mTOR activation during the myometrial proliferative phase of pregnancy, mTOR has emerged as a major effector of cell growth and proliferation (37) . These processes are tightly coordinated because every cell must attain a critical size before it can undergo division. There is a cross talk between the nutrient regulated mTOR pathway and the growth factor regulated PI3K pathway, which ensures that cell proliferation only occurs when amino acids, energy, and growth factors are in sufficient supply (25) . Both the mTOR and PI3K signaling pathways have been widely shown to regulate cell proliferation, evidenced by the fact that RAPA and wortmannin inhibit cell cycle progression by inducing an accumulation of cells in the G 1 phase (38) .
S6K1 and 4EBP1 are the best-characterized downstream targets of PI3K/Akt/mTOR signaling. The phosphorylated form of S6K1 was up-regulated during the proliferative phase of pregnancy as well as in response to E 2 stimulation in the OVX model. mTOR's other downstream target, 4EBP1, was phosphorylated equally throughout gestation but was nevertheless activated in response to E 2 treatment. S6K1 was shown to be catalytically active throughout the cell cycle in HeLa cells, with the highest level in the M phase (39) , suggesting that S6K1 may play an essential role in the proliferation of the rat uterine myocytes through its well-characterized role in cell cycle progression. 4EBP1 is one of the molecules that regulates the rate of cell cycle progression by inhibiting protein translation. However, when 4EBP1 is phosphorylated by mTOR, it loses its inhibitory role. We did not detect any change in the phosphorylation levels of 4EBP1 throughout gestation, which suggests that this protein may not play an essential role during myometrial SMC proliferation.
Over the past 25 yr, immunohistochemistry for the expression of Ki67 has been widely used to identify proliferating cells in all active phases of the cell cycle (30) . In OVX animals treated with E 2 alone, we found a very large population of Ki67-positive myometrial cells at all time points studied, confirming the ability of this ovarian hormone to induce uterine myocyte hyperplasia. Importantly, in the animals treated with E 2 ϩRAPA, we detected a significantly lower number of Ki67-positive cells, paralleled with the decrease in the phosphorylation of mTOR, S6K1, and 4EBP1, confirming that the E 2 -induced myometrial hyperplasia is directly dependent on mTOR signaling. Our data are in accordance with earlier results by Korach et al. (40) demonstrating that the proliferation of mouse uterine epithelia could be regulated by E 2 alone. Moreover, Suzuki et al. (41) demonstrated that the 5-bromo-2Ј-deoxyuridine labeling index in epithelial cells of the uterus and vagina was significantly increased in the animals treated with E 2 compared with control animals. Interestingly, these researchers also found that E 2 increases IGF-I mRNA and mitosis in the uterus and vagina, which corroborates with our results.
In summary, our data provide new understanding of the molecular mechanism responsible for myometrial SMC proliferation. We present the first in vivo evidence that E 2 activates the PI3K/mTOR signaling pathway in the myometrium, leading to uterine myocyte proliferation. The increase in IGF-I coincides with the up-regulation of mTOR pathway, which raises the possibility that IGF-I may stimulate such activation. However, we cannot rule out the possibility that during gestation in parallel with estrogens steroid hormone progesterone plays a role in the regulation of mTOR cascade. We propose that the hormone-induced activation of the mTOR signaling pathway mediates the hyperplasia of the uterine myocytes during the proliferative phase of rat gestation. Further analysis of the regulation of mTOR will provide insight into the potential process(es) that cause the transition between the proliferative and the synthetic phase of gestation and will ultimately heighten our understanding of mTOR's unique role in uterine myocyte differentiation during pregnancy. 
